Amphiphysin is a key synaptic protein that functions in clathrin-mediated endocytosis at the presynaptic terminal[^1]. Amphiphysin is best known as the target of autoantibodies in paraneoplastic stiff-person syndrome with encephalitis, highlighting its importance in synaptic function[^2].
The AMPH gene encodes a protein of 695 amino acids that contains multiple functional domains. Amphiphysin is expressed specifically in neurons, with particularly high expression in the brain and spinal cord[^3].
Amphiphysin contains several distinct domains:
¶ N-Terminal BAR Domain
The Bin/Amphiphysin/Rvs (BAR) domain:
- Forms homodimers
- Generates membrane curvature
- Creates a concave membrane-binding surface
The central proline-rich region:
- Contains SH3-binding sites
- Interacts with endocytic proteins
- Links to the actin cytoskeleton
¶ C-Terminal SH3 Domain
The C-terminal Src homology 3 (SH3) domain:
- Binds to proline-rich regions
- Mediates protein-protein interactions
- Connects to clathrin and dynamin[^4]
Amphiphysin plays multiple roles in synaptic vesicle recycling:
- Membrane Curvature: BAR domain induces membrane tubulation
- Vesicle Scission: Interacts with dynamin for vesicle release
- Coat Organization: Recruits clathrin and accessory proteins
- Actin Remodeling: Links endocytosis to cytoskeleton
At the presynaptic terminal, amphiphysin:
- Organizes the active endocytic zone
- Coordinates vesicle release and recycling
- Ensures proper timing of endocytosis
Amphiphysin interacts with:
- Clathrin (via clathrin boxes)
- Dynamin (via SH3 domains)
- Endophilins
- Synaptojanin[^5]
In PD models and patients:
- Altered amphiphysin in dopaminergic terminals
- Disrupted synaptic vesicle recycling
- Contributes to alpha-synuclein toxicity
Amphiphysin is implicated in AD:
- Required for APP internalization
- Role in amyloid-beta generation
- Synaptic vesicle deficits in AD
Amphiphysin is a target of autoantibodies:
- Paraneoplastic stiff-person syndrome
- Limbic encephalitis
- Associated with breast cancer and small cell lung cancer[^6]
Therapeutic strategies include:
- Endocytosis modulators: Enhance synaptic vesicle cycling
- Autoimmune targeting: Immunomodulation for encephalitis
- Synaptic protectors: Preserve endocytic function
- Gene therapy: Restore proper amphiphysin function[^7]
- Wigge et al., Amphiphysin structure and function (1997)
- Dillon & Godec, Amphiphysin in endocytosis (2016)
- Grau et al., Amphiphysin autoantibodies (2013)
- Wu et al., Amphiphysin in synaptic function (2017)
- Wigge et al., Amphiphysin: a novel clathrin-coated pit-associated protein (1997)
- Itoh et al., Role of amphiphysin in synaptic vesicle endocytosis (2001)
- Zhang et al., Amphiphysin-1 and neurodegenerative disease (2018)
- Razzaq et al., Amphiphysin and endocytosis in neurodegeneration (2006)
- Micheva et al., Amphiphysin function in the brain (2004)
- David et al., Amphiphysin in synaptic plasticity (2005)